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Abstract 
women and girls are especially vulnerable to HIv in-
fection in sub-saharan africa, and in some of those
countries, prevalence among young women can be up
to 3 times higher than among men of the same age.
Effective  HIv  prevention  options  for  women  are
clearly needed in this setting. several aRv-based vagi-
nal microbicides are currently in development for pre-
vention of HIv transmission to women and are dis-
cussed here. the concept of pre-exposure prophylaxis
for the prevention of HIv transmission to women is
introduced.
Key  words: microbicides,  HIv  prevention,  pre-expo-
sure  prophylaxis  (PrEP),  antiretrovirals,  vaginal  gel,
vaginal ring
Abbreviations:
aRv = antiretroviral (drug)
atn = adolescent Medicine trials network
bMgf = bill & Melinda gates foundation
caPRIsa = centre for the aIds Programme of Re-
search in south africa
EMa = European Medicines agency
fda = U.s. food and drug administration
fHI = family Health International
ftc = Emtricitabine
HEc = Hydroxyethyl cellulose
IavI = International aIds vaccine Initiative
IPM = International Partnership for Microbicides
Mtn = Microbicide trials network
nIaId = national Institute of allergy and Infectious
diseases
nIcHd = national Institute of child Health & Hu-
man development
nnRtI  =  non-nucleoside  reverse  transcriptase  in-
hibitor
nRtI = nucleoside reverse transcriptase inhibitor
PrEP = Pre-exposure prophylaxis
tdf = tenofovir disoproxil fumerate
UsaId = United states agency for International de-
velopment
voIcE = vaginal and oral Interventions to control
the Epidemic (trial)
IntRodUctIon
current  HIv  incidence  rates  in  highly  impacted  re-
gions reflect the magnitude of the epidemic and point
out  an  apparent  lack  of  HIv  prevention  methods,
specifically for women. sixty-eight percent of the 2.3
million adults newly infected with HIv in 2008 live in
sub-saharan africa, where approximately 60% of in-
fected individuals are women [1]. women and adoles-
cent girls are especially vulnerable to HIv infection in
sub-saharan africa not only because of their increased
physiological  susceptibility  to  heterosexual  transmis-
sion, but also because of social, legal, and economic
disadvantages [1]. according to the most recent esti-
mate, the number of people living with HIv is 33.4
million [1]. In the nine countries in southern africa af-
fected  most  by  HIv  (botswana,  lesotho,  Malawi,
Mozambique, namibia, south africa, swaziland, Zam-
bia, and Zimbabwe), prevalence among young women
aged 15-24 years was reported to be approximately 3
times  higher  than  among  men  of  the  same  age  [2].
HIv prevention options for women are presently lim-
ited in this setting.
Microbicides to prevent HIv infection in women
are  vaginally  applied  topical  products  that  interfere
with HIv infection at one or more steps in the replica-
tion cycle. this paper summarizes research to date on
early generation product development efforts (polyan-
ions, surfactants, acidifying agents) and next genera-
tion antiretroviral (aRv)-based HIv microbicides and
introduces  the  concept  of  pre-exposure  prophylaxis
(PrEP) for the prevention of HIv transmission.
tHE nEEd foR a fEMalE-InItIatEd HIv
PREvEntIon MEtHod
Half of the exposed population currently has no ef-
fective means of self-initiated HIv prevention; and al-
though condoms provide good protection from HIv
infection, their regular use is not always negotiable by
women.  the  effectiveness  of  an  HIv  prevention
method is impacted by its correct and consistent use.
therefore, microbicide research and development has
also focused on the topic of adherence, and factors af-
fecting adherence, such as preferred dosage forms and
regimens, stigma associated with microbicide use, male
perception  of  microbicide  use,  and  various  dosage
forms and regimens. 
an ideal microbicide product would be highly effec-
tive  against  HIv  transmission  and  potentially  other
pathogens, have a very good safety profile, create no
drug-drug  interactions  with  other  vaginal  products,
and could be easily and discreetly used on a regular ba-
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ent ideally would be long enough so that protective
drug levels would be maintained in tissues even with
lapses in product use. dosing regimens should accom-
modate the range in female sexual behavior from regu-
lar intercourse to periods of abstinence. long-acting
dosage forms such as vaginal rings may be an attrac-
tive feature for women as well as improve adherence
and therefore the effectiveness of the product. Prod-
uct formulations that combine HIv prevention with
contraception are in early stages of development and
would offer women additional options [3]. 
ovERvIEw of REsEaRcH and dEvEloPMEnt
EffoRts wItH non-aRv-basEd
MIcRobIcIdEs
several early generation microbicide gels were evaluat-
ed for efficacy in phase IIb and phase III trials with
disappointing  results.  these  include  the  surfactants
nonoxynol-9  [4]  and  savvY  (cellegy  Pharmaceuti-
cals, Huntington valley, Pa, Usa) [5]; three polyan-
ions,  cellulose  sulfate  [6],  carraguardﾮ (Population
council,  new  York,  nY,  Usa)  [7],  and  PRo  2000
(Endo Pharmaceuticals, chadds ford, Pa, Usa) [8];
and  an  acidifying  agent,  buffergel  (ReProtect  llc,
baltimore, Md, Usa) [8]. none proved to inhibit HIv
infection,  and  in  fact  with  three  of  the  gels,
nonoxynol-9, cellulose sulfate, and savvY, a trend to-
ward increased risk of HIv infection was observed [4-
6].
ovERvIEw of REsEaRcH and dEvEloPMEnts
EffoRts wItH aRv-basEd MIcRobIcIdEs
Microbicide research has now shifted to development
of next-generation, aRv-based formulations in multi-
ple  dosage  forms  such  as  vaginal  gels,  rings,  films,
soft-gel capsules, and tablets [9-11]. formulations of
aRvs  that  target  reverse  transcriptase  are  furthest
along in development as topical microbicides (table
1). Proof-of-concept was shown recently with a vagi-
nal gel containing tenofovir, an nRtI.
.
tEnofovIR
In July 2010, positive results were reported from the
caPRIsa 004 trial in south africa [12]. when com-
pared with the HEc-based universal placebo gel, 1%
tenofovir gel was 39% effective (incidence rate ratio
0.61, p = 0.017) at reducing new HIv infection after
30 months of coitally-dependent use by sexually-active
women  aged  18  to  40  years.  the  effectiveness  in-
creased to 54% (p = 0.025) when only data for women
who used the gel correctly were analyzed. the protec-
tive effect of tenofovir gel was evident at 6 months,
50% at 12 months (p = 0.007), and was 40% at 24
months  (p  =  0.013).  tenofovir  gel  had  a  favorable
safety profile: only diarrhea and gastrointestinal infec-
tions were significantly higher in the tenofovir gel vs.
placebo gel group (17% vs. 11%, p = 0.02). 
an ongoing study (Mtn 003, also referred to as
the  “vaginal  and  oral  Interventions  to  control  the
Epidemic” or “voIcE” trial) funded by nIaId and
sponsored by the Microbicide trials  network is being
conducted  in  africa  (Malawi,  south  africa,  Uganda,
Zimbabwe) to test the effectiveness of daily 1% teno-
fovir gel vs. placebo gel as well as the effectiveness of
oral  tenofovir  disoproxil  fumarate  (vireadﾮ,  gilead
sciences,  foster  city,  ca,  Usa)  and  oral  emtric-
itabine/tenofovir  disoproxil  fumarate  (truvadaﾮ,
gilead sciences) vs. oral placebo measured by HIv se-
roconversion.  Extended  safety  of  the  products  in
women at risk for sexually transmitted HIv infection
will also be assessed. the results of this study may an-
swer the question whether daily dosing (used in the
voIcE trial) improves adherence and effectiveness of
tenofovir gel compared with coitally-associated dosing
(used  in  the  caPRIsa  trial)  without  compromising
the safety profile. the results of the voIcE trial are
expected in 2013.
daPIvIRInE
dapivirine, an nnRtI initially developed by tibotec
Pharmaceuticals in belgium, has been tested for safety
in sexually active, HIv-negative women in both vaginal
gel  (daily  dosing)  and  vaginal  ring  (monthly  dosing)
formulations. both dosage forms have been shown to
have similar safety profiles to their respective placebos
and to release dapivirine into the lower female genital
tract at concentrations well above those shown to be
protective in vitro and ex vivo, and well above concen-
trations in plasma that have been shown to reduce vi-
ral load [13-19]. two more recently developed formu-
lations  of  0.05%  dapivirine  gel  have  been  tested  in
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Table 1. aRv-based Microbicides Products in development.
Product MOA License Holder(s) Phase of Development
tenofovir gel nRtI conRad and IPM Phase IIb 
dapivirine gel and ring nnRtI IPM Phase I/II
dapivirine–maraviroc combination gel and ring nnRtI + ccR5 blocker IPM Phase I planned
Maraviroc ring and gel ccR5 blocker IPM Phase I planned
Maraviroc–tenofovir combination film ccR5 blocker + nRtI IPM late preclinical 
MIv-150 gel and ring nnRtI Population council late preclinical 
1) Kaptur_Umbruchvorlage  14.01.11  12:05  Seite 2safety studies in kenya, Malawi, Rwanda, south africa,
and the United states. a safety study with the current
dapivirine  ring  formulation  (25  mg)  is  ongoing  in
south africa, kenya, and Malawi, and two pharmaco-
kinetics studies with the ring were recently completed
in belgium. 
MaRavIRoc
Maraviroc, a ccR5 co-receptor antagonist marketed as
selzentryﾮ (Pfizer  labs,  new  York,  nY,  Usa)  for
treatment of ccR5-tropic HIv-1 infection, is in devel-
opment as a vaginal microbicide [20]. vaginal gels and
rings containing a combination of dapivirine plus mar-
aviroc are in development; phase I clinical trials are
planned for 2011. these products have the potential
advantage of blocking HIv infection at two different
steps in the replication cycle, attachment and reverse
transcription. vaginal gels and rings containing mar-
aviroc as a single agent are in development in parallel
with the combination dosage forms and will be includ-
ed in the phase I clinical trials planned for 2011. In ad-
dition, a combination vaginal film with maraviroc and
tenofovir is in preclinical development.
MIv-150
MIv-150  is  an  nnRtI  with  potent  activity  against
HIv-1 and HIv-2, including free HIv-1 and HIv-1
strains that are resistant to other aRvs [21-22]. MIv-
150  is  currently  under  development  at  Population
council  in  both  microbicide  gel  (Pc-815  and  Pc-
1005)  and  ring  formulations  [23-25].  Population
council researchers are also developing vaginal rings
that  contain  both  MIv-150  and  a  contraceptive  to
protect women against both HIv infection and preg-
nancy.
cHallEngEs facEd In MIcRobIcIdE
dEvEloPMEnt
the establishment of surrogate markers for determi-
nation of clinical efficacy and survival-enhancing ef-
fects of aRvs (rises in cd4 cell counts and decreases
in HIv viral load) dramatically enhanced the develop-
ment of new medicines for the treatment of HIv in-
fection [26, 27]. to date, no surrogate markers have
been  identified  for  measurement  of  the  efficacy  of
HIv prevention tools; therefore, microbicide clinical
trials are designed to measure the difference in infec-
tion rates between the active and control groups. for
this reason, trial settings must have sufficiently high
HIv incidence rates (typically over 2%) to show a sig-
nificant reduction with the intervention. furthermore,
careful selection of microbicide candidates to test in
clinical trials is imperative because of shared trial sites
and high trial expenses. because of the lack of surro-
gate markers, in vitro assays, cervical explant models,
and animal models have been utilized to estimate the
potential for preventive efficacy of new microbicide
compounds in women. these models are experimental
and  have  not  been  validated.  the  development  of
pharmacokinetic/pharmacodynamic  models  is  being
explored [28] and ideally would be able to predict the
pharmacodynamic  effect  of  a  microbicide  candidate
from the pharmacokinetic profile.
adherence with the microbicide regimen is general-
ly measured in clinical trials by self-reported product
use and counting of returned used and unused gel ap-
plicators [29]. this provides only an estimate of true
adherence and no information on the time of product
insertion. others have explored “daily monitored ad-
herence” and found that daily contact with trial partic-
ipants can improve adherence to the microbicide regi-
men [30]. 
Use of aRv-based vaginal microbicides could po-
tentially induce drug resistance in individuals who are
unaware that they are HIv infected if subtherapeutic
drug levels consistent with the selection of resistance
in vivo are attained. systemic drug exposure after vagi-
nal  dosing  with  nRtI-  and  nnRtI-based  microbi-
cides has been shown to be low [13, 14, 16, 17, 18, 31,
32], while concentrations in cervicovaginal fluids have
been shown to be many logs greater than in vitro con-
centrations at which resistance mutations were noted
[13].  combination  microbicides  with  two  drugs  that
target different steps in the HIv replication cycle may
reduce the potential for development of HIv resis-
tance by increasing the barrier to infection [28, 33].
furthermore, combination microbicides may help pre-
vent the transmission of virus resistant to a specific
drug via the mechanism of action of the other drug 
in the combination. development of resistance is be-
ing studied in the clinical context through the imple-
mentation  of  seroconvertor  protocols  [12,  13].  the
monitoring of microbicide users for HIv infection is
therefore important, and recommended timetables for
HIv  testing  are  under  development.  Monthly  HIv
testing is generally used in microbicide trials; however,
this  schedule  may  not  be  feasible  after  product  ap-
proval. 
PRIoRItIEs In MIcRobIcIdE dEvEloPMEnt
now that proof-of-concept for an aRv-based vaginal
microbicide has been established through the success-
ful completion of the caPRIsa trial [12], interest in
new HIv prevention tools has received a boost. It is
now a priority to set-up the necessary confirmatory
and supporting studies for the continued clinical de-
velopment of tenofovir gel, which could then lead to
the approval and launch of the first aRv-based micro-
bicide.  other  aRv-based  microbicides  that  hold
promise for increasing potency and addressing prod-
uct adherence concerns need to be prioritized for de-
velopment, including products ready for efficacy test-
ing such as the dapivirine-containing vaginal ring.
optimizing implementation programs and measur-
ing the real-life public health impact will be further
milestones. Establishment of a comprehensive post-
approval drug safety surveillance system is important
when microbicides are introduced into the markets in
developing  countries  because  there  is  no  experience
with the use of these products in regions under the ju-
risdiction  of  the  fda  or  EMa.  also,  since  these
products  will  be  used  by  otherwise  healthy  women,
monitoring product safety is paramount. further de-
velopment  of  aRv-based  microbicides  (including
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1) Kaptur_Umbruchvorlage  14.01.11  12:05  Seite 4drug  combinations)  with  longer-acting  formulations
and in multiple dosage forms remains a priority to of-
fer women choices, a strategy that has proven to be
very successful in the field of contraception [34, 35].
PRE-ExPosURE PRoPHYlaxIs (PREP)
In  addition  to  HIv  microbicide  development,  oral
PrEP of HIv infection with aRv drugs approved for
treatment of HIv and aIds is currently under inves-
tigation [36-39]. the voIcE trial described above is
one  such  trial.  other  PrEP  trials  being  conducted
worldwide are shown in table 2. all but one of these
trials is with oral tenofovir disoproxil fumarate and/or
oral emtricitabine plus tenofovir disoproxil fumarate.
Intramuscular  injection  of  tMc278la,  an  nnRtI
for  HIv  prevention,  is  presently  being  tested  in  a
phase I trial in the Uk. the results of the first oral
PrEP  trials  in  women  are  expected  in  2010  and 
2011. 
the findings of these PrEP trials should hopefully
demonstrate  the  efficacy,  safety,  and  tolerability  of
aRvs in HIv-negative individuals. In addition, the re-
sults will be used to develop public health guidelines
for prevention of HIv transmission in different popu-
lations  such  as  heterosexual  couples,  serodiscordant
couples, men who have sex with men, and injection
drug users. If proven safe and effective, PrEP could
help  address  the  urgent  need  for  a  female-initiated
prevention method for women worldwide.
conclUsIons
there is an immediate need for female-initiated HIv
prevention tools. Microbicide research, like most HIv
prevention research, has faced many hurdles over the
past  two  decades,  but  proof-of-concept  in  the
caPRIsa  trial  has  reignited  the  hope  of  obtaining
safe and effective HIv microbicides that are accept-
able to the women who will use these products. sever-
al aRv-based microbicides are in clinical trials at this
time, and many others are in preclinical stages of de-
velopment. oral PrEP with aRvs approved for treat-
ment of HIv/aIds is currently under investigation
with  the  first  trial  results  expected  in  2010  and 
2011.
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